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De novo urological malignancies in renal 
transplant recipients
Hugo Antunes, Edgar Tavares-Da-Silva, Rui Oliveira, João Carvalho, Belmiro Parada, Carlos Bastos, Arnaldo Figueiredo
• Sixty-one de novo urological malignancies were recorded in 58 patients.
• The overall incidence of urological malignancies was 2,2%.
• Tumor-related death was found in 13,8% of patients.
• Twenty-five (43,1%) cases had graft loss. Of these, 11 patients had a
non functional graft when the diagnosis of urologic tumor was made.






We conducted a cross-sectional single-center
study of 2897 patients who underwent renal
transplantation between January 1987 and
December 2016. Recipients presenting de novo
urological malignancies were evaluated regarding
type of cancer, treatments and their results
posttransplant duration, immunosuppressive
regimens, graft functional status. We
retrospectively assessed the stage of the disease,
treatment performed and consequent oncologic
outcome. Patients with a history of pre-existing
cancers were excluded.
Renal transplantation has evolved greatly in recent
years, with graft and patient survival increasing.
Part of this success is due to the development and
application of new immunosuppressive drugs.
Immunosuppressed transplant patients have an
higher risk of malignancies development. The aim
of this study was to determine the incidence of
urological malignancies in renal transplant
recipients, as well as to evaluate their monitoring,
treatment and outcomes.
Renal transplant patients have a high incidence of
urological tumors. Treatment of these tumors is
not different from the rest of the patients.
However, due to the increased incidence of tumors
and possibly worse prognosis, renal transplant
recipients should be screened more regularly.














29/0 17/5 6/0 1/0 53/5
Age at renal 
transplantation 
(years)
53.4±10.7 44.8±10.4 58.8±9.3 58±9.9 50.6±11.2
Age at tumor 
diagnosis (years)
62.6±6.1 52.1±11.0 66.8±3.2 58 58.7±10.1
Deceased 
donor/living donor
29/0 21/2 6/0 1/0 56/2
Time period of 
dialysis until renal 
transplant (months)
39.8±31.6 54.1±48.1 43.0±22.5 16 45.3±38.2
Time between renal 
transplant and tumor 
diagnosis (months)
108±85 114±96 102±113 3 108.2±90.9
Overall-survival 5-
year after tumor 
diagnosis (%)
86.2 91.3 83.3 100 84.5
Incidence rate (%) 1.5 0.8 0.2 0.04 2.2
n/a not applicable 
